Senators question Allergan CEO on tribe patent deal
Por um escritor misterioso
Descrição
A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.
Speaker Bios Do Not Delete - Foundry Events
Allergan Gains Another Approval for Botox Amid Patent Controversy Over Restasis - Xtalks
U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents
Allergan deal with Mohawk tribe casts patent shadow
Senators blast Allergan's tribal deal, social contract as 'hypocrisy
Allergan plc
Senators blast Allergan's tribal deal, social contract as 'hypocrisy
Page 67 – Business North Carolina
The top 15 drug patent expirations of 2018
Selling Sovereignty: How Corporations Used Tribal Sovereign Immunity to Evade Regulation and Exploit Consumers - The Flaw
de
por adulto (o preço varia de acordo com o tamanho do grupo)
